Market Access What the revised 340B rebate pilot programme means for pharm... While the scope of the revised pilot is limited, it may be a harbinger for a broader policy shift.
News Another 340B lawsuit gets underway, in Illinois Three pharma groups have opened a new front in their legal challenge to the federal 340B drug pricing programme in the US.
News AbbVie tries a new approach in 340B programme battle AbbVie has opened a new front in the pharma industry's efforts to reform the 340B drug discounting programme for safety net hospitals in the US.
News US court says pharma giants must face False Claims suit An appeals court in the US has said AbbVie, AstraZeneca, Novartis, and Sanofi must defend claims they defrauded federal and state governments.
News Court blocks HHS' 340B rebate programme pilot Hospitals that challenged a US pilot of a new rebate model for medicines provided to low-income people have won another legal victory.
News Judge blocks HHS' 340B rebate pilot at 11th hour A federal judge in the US has granted a restraining order that will stop the 340B rebate model from launching as planned on 1st January.
News Iambic prices its IPO, seeking to raise up to $160m AI-powered drug discovery company Iambic Therapeutics has announced the terms of its Nasdaq IPO, pitching at a valuation of more than $800m.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
